ALDEYRA THERAPEUTICS INC (ALDX)

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Notable Thursday Option Activity: ESTC, CRNC, ALDX

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

ALDX Crosses Below Key Moving Average Level

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Noteworthy Thursday Option Activity: APPS, ALDX, COIN

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

Commit To Purchase Aldeyra Therapeutics At $2.50, Earn 16.6% Annualized Using Options

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Aldeyra Therapeutics to Host Investor Roundtable Q&A

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

Bullish Two Hundred Day Moving Average Cross - ALDX

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024

ALDX stock results show that Aldeyra Therapeutics met analyst estimates for earnings per share the first quarter of 2024.

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

Commit To Purchase Aldeyra Therapeutics At $2.50, Earn 25.2% Annualized Using Options

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

Commit To Purchase Aldeyra Therapeutics At $2.50, Earn 22% Using Options

Aldeyra stock jumps 8% on dermatitis drug updates (NASDAQ:ALDX)

Aldeyra Therapeutics (ALDX) shares jumped 8% on updates for two of its drug candidates for atopic dermatitis. Read more here.

Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

3 Stocks at the Forefront of Personalized Medicine Trend

Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly

FDA says more data needed to approve Aldeyra dry eye drug (NASDAQ:ALDX)

The FDA has declined to approve Aldeyra's (ALDX) drug reproxalap for dry eye disease, stating the company needs to run at least one additional study to show its effectiveness.

FDA says more studies needed to approve Aldeyra dry eye drug (NASDAQ:ALDX)

The FDA has declined to approve Aldeyra's (ALDX) drug reproxalap for dry eye disease, stating the company needs to run at least one additional study to show its effectiveness.

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease